Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9915023 | 1.00 | CA1 (0.35) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL17920111 | 1.00 | CA1 (0.35) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL19955121 | 0.90 | KDM4C (0.40) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL15187247 | 0.85 | MMP9 (0.32) | — | |
| SCHEMBL17920012 | 0.85 | MMP9 (0.32) | — | |
| SCHEMBL17920016 | 0.85 | MMP9 (0.32) | — | |
| SCHEMBL25919388 | 0.84 | GAA (0.31) | — | |
| SCHEMBL16022889 | 0.81 | ALDH1A1 (0.46) | KDM4CKDM4APHF8CHRNB2CHRNA4 | |
| SCHEMBL20880284 | 0.81 | CA1 (0.32) | CA1 | |
| SCHEMBL16360268 | 0.79 | CA1 (0.38) | CA1KDM4CKDM4APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200767-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2016112321-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-20120088734-A1 | Cyclosporin Analogs | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20100279951-A1 | METHOD OF TREATING ALLERGIC CONJUNCTIVITIS WITH CYCLOSPORIN COMPOSITIONS | SAINT REGIS MOHAWK TRIBE | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088734-A1 | Cyclosporin Analogs | CHP1, TSLP, PPP3R1 | CA1 4455/4885KDM4C 4765/4885KDM4A 4739/4885 |
| US-20100279951-A1 | METHOD OF TREATING ALLERGIC CONJUNCTIVITIS WITH CYCLOSPORIN COMPOSITIONS | TSLP, CHP1, MALT1 | CA1 2290/4885KDM4C 3862/4885KDM4A 4314/4885 |
| US-20160200767-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | CHP1, PPIB, FKBP1B | CA1 2159/4885KDM4C 4602/4885KDM4A 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.